Chemistry: molecular biology and microbiology – Enzyme – proenzyme; compositions thereof; process for... – Enzyme inactivation by chemical treatment
Reexamination Certificate
2008-10-06
2011-11-15
Loewe, Sun Jae (Department: 1622)
Chemistry: molecular biology and microbiology
Enzyme , proenzyme; compositions thereof; process for...
Enzyme inactivation by chemical treatment
C435S375000, C514S217050, C514S235800, C514S252110, C514S253010, C514S255050, C540S120000, C544S295000, C544S405000
Reexamination Certificate
active
08058045
ABSTRACT:
The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain biarylamine compounds (referred to herein as BAA compounds), and especially certain pyrazin-2-yl-pyridin-2-yl-amine and pyrazine-2-yl-pyrimidin-4-yl-amine compounds of formula (I), which, inter alia, inhibit Checkpoint Kinase 1 (CHK1) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK1 kinase function, and in the treatment of diseases and conditions that are mediated by CHK1, that are ameliorated by the inhibition of CHK1 kinase function, etc., including proliferative conditions such as cancer, etc., optionally in combination with another agent, for example, (a) a DNA topoisomerase I or II inhibitor; (b) a DNA damaging agent; (c) an antimetabolite or TS inhibitor; (d) a microtubule targeted agent; and (e) ionisiπq radiation, wherein: —X═ is independently —CRA5═ or —N═; and the rest of the substituents are as specified in the claims.
REFERENCES:
patent: WO 03/032984 (2003-04-01), None
patent: WO 03/035065 (2003-05-01), None
patent: WO 03/093297 (2003-11-01), None
patent: WO 03/101444 (2003-12-01), None
patent: WO 2005/011597 (2005-02-01), None
patent: WO 2005/034869 (2005-04-01), None
patent: WO 2005/037285 (2005-04-01), None
patent: WO 2005/121126 (2005-12-01), None
patent: WO 2006/039718 (2006-04-01), None
patent: WO 2007/000240 (2007-01-01), None
patent: WO 2008/077554 (2008-07-01), None
patent: WO 2008/115369 (2008-09-01), None
Gabriel et al., caplus an 1908:3563.
Wang et al., caplus an 2005:1155529.
Balaint and Vousden, 2001, “Activation and activities of the p53 tumour suppressor protein,”Br. J. Cancer, vol. 85, pp. 1813-1823.
Bartek and Lukas, 2003, “Chk1 and Chk2 kinases in checkpoint control and cancer,”Cancer Cell, vol. 3, pp. 421-429.
Carson and Lois, 1995, “Cancer progression and p53,”Lancet, vol. 346, pp. 1009-1011.
Dixon and Norbury, 2002, “Therapeutic exploitation of checkpoint defects in cancer cells lacking p53 function,”Cell Cycle, vol. 1, pp. 362-368.
Greenblatt et al., 1994, “Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis,”Cancer Res., vol. 54, pp. 4855-4878.
Itoh et al., 2002, “Efficient synthesis of substituted 2-aminopyrazines: FeCI3-promoted condensation of hydroxyiminoketones with aminoacetonitriles”,Tetrahedron Lett., vol. 43, pp. 9287-9290.
Liu et al., 2000, “Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint,”Genes Dev., vol. 14, pp. 1448-1459.
Sanchez et al., 1997, “Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25,”Science, vol. 277, pp. 1497-1501.
Sorensen et al., 2005, “Cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair,”Nat. Cell Biol., vol. 7, pp. 195-201.
Tao and Lin, 2006, “Chk1 inhibitors for novel cancer treatment,”Anti-Cancer Agents in Medicinal Chemistry, vol. 6, pp. 377-388.
Wang et al., 1996, “UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53,”J. Natl. Cancer Inst., vol. 8, pp. 956-965.
Weinert and Hartwell, 1989, “Control of G2 delay by the rad9 gene ofSaccharomyces cerevisiae,”J. Cell Sci. Suppl., vol. 12, pp. 145-148.
White et al., 1967, “Gattermann reaction of 3,5-dimethoxyphenylacetonitrile. Synthesis of 6,8-dioxyisoquinolines”J. Org. Chem., vol. 32, pp. 2689-2692.
Xiao et al., 2006, “Differential roles of checkpoint kinase 1, checkpoint kinase 2, and mitogen-activated protein kinase-activated protein kinase 2 in mediating DNA damage-induced cell cycle arrest: implications for cancer therapy,”Mol. Cancer Ther., vol. 5, pp. 1935-1943.
Zachos et al., 2003, “Chk1-deficient tumour cells are viable but exhibit multiple checkpoint and survival defects,”EMBO J., vol. 22, pp. 713-723.
Zhao et al., 2002, “Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints,”Proc. Natl. Acad. Sci. USA, vol. 99, pp. 14795-14800.
International Search Report (ISR) and Written Opinion of International Searching Authority (WOISA) for PCT/GB2008/003362, 2008.
International Preliminary Report on Patentability (IPRP) for PCT/GB2008/003362, 2008.
International Search Report (ISR) and Written Opinion of International Searching Authority (WOISA) for PCT/GB2009/000438, 2009.
International Preliminary Report on Patentability (IPRP) for PCT/GB2009/000438, 2009.
UK Search Report for GB 0719644.7, 2008.
UK Search Report for GB 0803018.1, 2008.
Addison Glynn Jonathan
Cherry Michael
Cheung Kwai Ming
Collins Ian
Klair Sukhbinder Singh
Cancer Research Technology Limited
Loewe Sun Jae
Swanson & Bratschun L.L.C.
LandOfFree
Pyrazin-2-yl-pyridin-2-yl-amine and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrazin-2-yl-pyridin-2-yl-amine and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrazin-2-yl-pyridin-2-yl-amine and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4262507